Tadalafil Tablet, Film Coated
Product Images NDC 71335-1587

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1587). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351587)

Tadalafil 20 mg film-coated tablet label packaged by Bryant Ranch Prepack, Burbank, CA. The label compares the product to Cialis 20 mg tablets by Intas Pharmaceuticals Limited and includes storage instructions at 20°-25°C (68°-77°F). The package size is 30 tablets, with a visible NDC 71335-1587-1 and a barcode included.*

FDA Label Image

Figure (Tadalafil Figure1)

Four line graphs depicting changes in standing and supine systolic and diastolic blood pressure (BP) over time, measured in hours, comparing Tadalafil to placebo. Each graph shows the difference in BP (mmHg) from baseline at multiple time points up to 96 hours, with error bars indicating variability around the mean difference.*

FDA Label Image

Figure (Tadalafil Figure2)

Two line graphs showing the effects on systolic blood pressure over 24 hours post-dose. The top graph depicts standing systolic blood pressure versus time for Tadalafil 20 mg combined with doxazosin 8 mg and placebo with doxazosin 8 mg. The bottom graph shows supine systolic blood pressure versus time for the same treatments. Each graph plots the change in blood pressure in mmHg over time in hours post-dose.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph showing systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo. The graph compares 20 mg tadalafil dosed at 08:00 and 20:00 combined with 8 mg doxazosin at 08:00 against corresponding placebo groups, illustrating fluctuations in blood pressure over time for each treatment condition.*

FDA Label Image

Figure (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dosing over 5 consecutive days. The y-axis shows concentration up to 500 µg/L, and the x-axis shows time up to 120 hours, with data points connected by dashed or solid lines and error bars displayed.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment with tadalafil 5 mg and placebo. The x-axis shows treatment duration in weeks, and the y-axis shows score changes, with tadalafil showing a greater reduction in IPSS score compared to placebo over time.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph showing change from baseline in IPSS total score over 12 weeks of treatment, comparing tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows change in IPSS total score. Data points for tadalafil 5 mg show a greater decrease over time compared to placebo, with statistical significance indicated for some points.*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line graph comparing the least squares mean change from baseline over 26 weeks of therapy between two treatment groups: Tadalafil/Finasteride and Placebo/Finasteride. The x-axis shows weeks of therapy (0, 4, 12, 26), and the y-axis shows LS mean change from baseline with values ranging from 0 to -7. Tadalafil/Finasteride shows greater reduction over time compared to Placebo/Finasteride, with statistical significance markers for certain time points.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph comparing change from baseline in IPSS total score over a 12-week treatment duration, showing results for tadalafil 5 mg versus placebo. The x-axis represents duration of treatment in weeks and the y-axis shows change from baseline in IPSS total score. Tadalafil demonstrates a greater reduction in score compared to placebo, with significance indicated at the 12-week mark.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure of tadalafil, showing its molecular framework including fused rings and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.